Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The ILDS Newsletter reported on efforts to support albinism patients in Tanzania and dermatological conferences.

This study observed that dupilumab led to significant hair regrowth and was well-tolerated in children with both alopecia areata and atopic dermatitis, showing promise as a safe treatment option for pediatric patients with associated atopy.

Abrocitinib may help treat alopecia areata effectively with mild side effects.

This study found that dermal white adipose tissue surrounding human hair follicles enhances proliferation, pigmentation, and hair shaft elongation in an ex vivo setting.

Children with alopecia areata often face more stress and depression, especially related to separation, which can affect their condition.

In this study, researchers reported that individuals from iodine-deficient regions have an increased risk of developing hypothyroidism from MDR-TB treatment regimens containing PAS and/or Prothionamide.

In this study, researchers found a significant association between Alopecia Areata and depressive symptoms, with those diagnosed showing higher depression scores and differing responses in psychological assessments compared to controls.

This review examines topical immunotherapy for severe alopecia areata, noting that diphencyprone and squaric acid dibutylester are non-mutagenic options with similar efficacy but different practical considerations, and reports no new clinical results.

This study found that treatment with ritlecitinib led to significant scalp hair regrowth in patients with alopecia areata at Weeks 24 and 48, with higher response rates observed in those receiving 50 mg compared to 30 mg doses.

In this study, tofacitinib treatment for six months significantly reduced hair loss severity in alopecia areata patients.

In this study, baricitinib showed effectiveness and good tolerability in treating severe alopecia areata over 52 weeks.

This case report describes canities subita, characterized by sudden hair whitening without hair loss, in a patient following a stressful event, suggesting an immune system involvement.

This study found that oral JAK inhibitors, ruxolitinib and tofacitinib, are effective and well-tolerated for treating severe alopecia areata, with a similar degree of hair regrowth and relapse rates, but ruxolitinib induced faster initial hair regrowth.

This study resulted in a draft version of the Patient‐Reported Impact of Dermatological Diseases measure, PRIDD, which includes 27 items refined from patient consensus and is now undergoing psychometric testing.

In this study, dry powder inhalers containing Cepharanthine were administered to rats with acute lung injury, significantly reducing pulmonary edema, hemorrhage, and inflammatory markers, suggesting its potential as an effective anti-inflammatory treatment when inhaled directly into the lungs.

This study found that an alternating inflatable head pad significantly reduced the incidence and severity of occipital pressure ulcers and alopecia in patients undergoing open heart surgery, suggesting improved postoperative nursing and patient quality of life.

Upadacitinib is effective and safe for treating severe Alopecia Areata in adolescents.

This case report found that a patient with ritlecitinib-resistant alopecia areata experienced significant recovery after 24 weeks of treatment with upadacitinib, highlighting its potential effectiveness and suggesting benefits of personalized treatment strategies targeting the JAK1-mediated pathway.

In this study, patients with alopecia areata who didn't initially respond to ritlecitinib at Week 24 showed improved response rates by Week 48, with up to 34% achieving better hair regrowth outcomes.

This study in a murine model of alopecia areata found that IFNg is crucial while perforin is not necessary for CD8 T cell-mediated disease development.

This guideline by the British Association of Dermatologists reviews managing alopecia areata and provides 56 recommendations but reports no new clinical results.

This case report describes significant improvement in a 23-year-old male with alopecia areata of toxic origin after 10 days of Ayurvedic treatment involving Shamana and Shodhana therapies, as new hair emerged.

This study found that tofacitinib may be effective in treating various pediatric rheumatic diseases, particularly juvenile idiopathic arthritis, although some patients did not respond, and side effects were observed.

This study found that tofacitinib is an effective and more tolerable treatment than systemic corticosteroids for moderate-to-severe alopecia areata, and its combination with corticosteroids may offer improved efficacy.

This study found that evaluating nasal breathing parameters in children with adenoiditis may help assess the effectiveness of conservative treatments during outpatient care.

In this case report, a 23-year-old male with alopecia areata in the beard area experienced significant improvement, with tiny hairs appearing, after 10 days of combined Ayurvedic Shamana and Shodhana therapies.

This study introduces "alopecia areata in a male or female pattern distribution" as a new clinical subtype of alopecia areata, observed in three adult cases, to enhance diagnostic precision and treatment personalization.

Upadacitinib effectively treated severe hair loss in a child.

This study analyzed the features of alopecia areata incognita and diffuse alopecia areata, finding distinct patterns in hair loss regions and trichoscopic signs, and noted a benign course responsive to topical steroid therapy.

This study reviewed existing articles to assess the efficacy of topical diphenylcyclopropenone immunotherapy for alopecia areata, but it did not report new clinical results.